NKT cell adjuvants in therapeutic vaccines against hematological cancers

Immune adjuvants aimed at initiating or re-activating host immunity against poorly immunogenic cancers represent a potential tool for immunotherapy. By employing the natural killer T (NKT) cell agonist α-galactosylceramide in a whole tumor cell therapeutic vaccine approach, we have achieved potent s...

Descripción completa

Detalles Bibliográficos
Autores principales: Mattarollo, Stephen R., Smyth, Mark J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583928/
https://www.ncbi.nlm.nih.gov/pubmed/23482240
http://dx.doi.org/10.4161/onci.22615
_version_ 1782475508328431616
author Mattarollo, Stephen R.
Smyth, Mark J.
author_facet Mattarollo, Stephen R.
Smyth, Mark J.
author_sort Mattarollo, Stephen R.
collection PubMed
description Immune adjuvants aimed at initiating or re-activating host immunity against poorly immunogenic cancers represent a potential tool for immunotherapy. By employing the natural killer T (NKT) cell agonist α-galactosylceramide in a whole tumor cell therapeutic vaccine approach, we have achieved potent suppression of established hematological cancers upon the elicitation of innate and adaptive antitumor immunity.
format Online
Article
Text
id pubmed-3583928
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-35839282013-03-11 NKT cell adjuvants in therapeutic vaccines against hematological cancers Mattarollo, Stephen R. Smyth, Mark J. Oncoimmunology Author's View Immune adjuvants aimed at initiating or re-activating host immunity against poorly immunogenic cancers represent a potential tool for immunotherapy. By employing the natural killer T (NKT) cell agonist α-galactosylceramide in a whole tumor cell therapeutic vaccine approach, we have achieved potent suppression of established hematological cancers upon the elicitation of innate and adaptive antitumor immunity. Landes Bioscience 2013-01-01 /pmc/articles/PMC3583928/ /pubmed/23482240 http://dx.doi.org/10.4161/onci.22615 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Mattarollo, Stephen R.
Smyth, Mark J.
NKT cell adjuvants in therapeutic vaccines against hematological cancers
title NKT cell adjuvants in therapeutic vaccines against hematological cancers
title_full NKT cell adjuvants in therapeutic vaccines against hematological cancers
title_fullStr NKT cell adjuvants in therapeutic vaccines against hematological cancers
title_full_unstemmed NKT cell adjuvants in therapeutic vaccines against hematological cancers
title_short NKT cell adjuvants in therapeutic vaccines against hematological cancers
title_sort nkt cell adjuvants in therapeutic vaccines against hematological cancers
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583928/
https://www.ncbi.nlm.nih.gov/pubmed/23482240
http://dx.doi.org/10.4161/onci.22615
work_keys_str_mv AT mattarollostephenr nktcelladjuvantsintherapeuticvaccinesagainsthematologicalcancers
AT smythmarkj nktcelladjuvantsintherapeuticvaccinesagainsthematologicalcancers

Ejemplares similares